title: Treatment of acute myeloid leukemia patients aged more than 75 years: results of the E-AML-01 trial of the Japanese Elderly Leukemia and Lymphoma Study Group (JELLSG).
abstract: The feasibility and effects of combination chemotherapy for very elderly patients with acute myeloid leukemia was examined in 65 patients (including previous myelodysplastic syndrome) aged 76 years or morewith a performance status of 0 - 3. Induction chemotherapy was performed with 30 mg/m2 daunorubicin on days 1 - 3, 150 mg/m2 behenoyl cytosine arabinoside on days 1 - 7, and 70 mg/m2 6-mercaptopurine with 300 mg allopurinol taken orally on days 1 - 7 (BHAC-DM). The complete remission (CR) rate was 38.5%, whereas overall survival at 2 and 5 years was 22.0% and 4.7%, respectively. Two- and 5-year survival of CR patients was 41.8% and 11.2%, respectively. The relapse rate of the 25 CR patients was 64.0% and disease-free survival at 2 and 5 years was 21.0% and 11.2%, respectively. The therapy-related mortality rate at induction was 13.8%. BHAC-DM is feasible and effective for selected very elderly acute myeloid leukemia patients.
authors.affiliation: Division of Hematology, Tokyo Metropolitan Geriatric Hospital, Sakaecho, Tokyo, Japan. mayumi_mori@tamahoku-hp.jp
authors.forename: Mayumi
authors.initials: M
authors.lastname: Mori
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Ohta
authors.forename: Akira
authors.initials: A
authors.lastname: Miyata
authors.forename: Masaaki
authors.initials: M
authors.lastname: Higashihara
authors.forename: Kazuo
authors.initials: K
authors.lastname: Oshimi
authors.forename: Hideo
authors.initials: H
authors.lastname: Kimura
authors.forename: Fumiharu
authors.initials: F
authors.lastname: Yagasaki
authors.forename: Kazutaka
authors.initials: K
authors.lastname: Sunami
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000494:pharmacology; D003561:Cytarabine / Q000031:analogs & derivatives / Q000494:pharmacology; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D012074:Remission Induction; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003561:Cytarabine; C015019:enocitabine